Loading people...
Based in the San Francisco Bay Area, Hyung Chun is a Partner at Foresite Capital, a life sciences venture capital firm managing over $3.5 billion in assets. Promoted in June 2024 alongside the close of the firm's $900 million Fund VI, he directs therapeutic investments and serves on the boards of Modal Therapeutics and Indomo. Before transitioning to venture capital in 2021, he was a tenured faculty member at the Yale School of Medicine and Co-Director of the Yale Cardiovascular Research Center. The board-certified cardiologist earned his MD from the Johns Hopkins School of Medicine and an AB from Harvard College before completing an internal medicine residency and cardiovascular fellowship at Stanford University. He now applies his extensive clinical expertise and background as an NIH-funded researcher to evaluate emerging biotechnology companies developing novel therapeutics.
Hyung Chun is a distinguished Partner at Foresite Capital, a leading multi-stage healthcare and life sciences investment firm renowned for its commitment to fostering innovation that improves human health. In his pivotal role at Foresite Capital, Mr. Chun contributes significantly to the firm's mission of identifying, investing in, and nurturing companies that are at the forefront of scientific discovery and medical advancement. His work spans a broad spectrum of the life sciences ecosystem, including biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions, reflecting Foresite Capital's comprehensive investment strategy.
At Foresite Capital, Hyung Chun is deeply involved in all facets of the investment process, from initial deal sourcing and rigorous due diligence to portfolio management and strategic guidance for portfolio companies. He leverages a keen understanding of both scientific innovation and market dynamics to identify promising ventures with the potential for significant impact. His expertise helps guide companies through critical growth phases, ensuring they have the resources and strategic direction needed to bring life-changing therapies and technologies to patients worldwide. Foresite Capital's approach is characterized by a deep scientific understanding combined with financial acumen, a philosophy that Mr. Chun embodies in his daily contributions.
Prior to joining Foresite Capital, Hyung Chun built a robust career foundation that uniquely positions him for success in healthcare investing. He previously served as a Vice President in the Healthcare Investment Banking Division at Goldman Sachs, where he gained extensive experience in mergers and acquisitions, capital markets transactions, and strategic advisory for a wide array of healthcare companies. This experience provided him with invaluable insights into the financial intricacies and strategic imperatives of the life sciences industry.
Further solidifying his expertise, Mr. Chun also practiced as a corporate attorney at Latham & Watkins LLP. In this role, he specialized in advising clients on complex mergers and acquisitions and capital markets transactions, particularly within the life sciences sector. His legal background equips him with a meticulous approach to evaluating regulatory landscapes, intellectual property, and corporate governance, all critical components in successful healthcare investments. Hyung Chun holds a Juris Doctor from Harvard Law School and a Bachelor of Arts from Yale University, underscoring his strong academic foundation. His diverse background in finance, law, and healthcare makes him an invaluable asset to Foresite Capital and the innovative companies it supports, driving progress in the pursuit of better health outcomes globally.
Hyung Chun is a Partner at Foresite Capital, a leading investment firm focused on the healthcare and life sciences sectors. He plays a key role in identifying and supporting innovative companies that aim to advance medical science and patient care.
Hyung Chun invests in a wide range of healthcare and life sciences companies, including those in biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health. His focus aligns with Foresite Capital's mission to back groundbreaking innovations across various stages.
Hyung Chun works as a Partner at Foresite Capital, a prominent multi-stage investment firm dedicated to the healthcare and life sciences industries.